Wegovy and other GLP-1 obesity and blood sugar control drugs accounted for 17% of pharmacy benefits spending at CBIZ employer clients with self-funded health plans in 2024, up from 13% in 2023, according to a new health care report. The broker’s clients spent spent $125 million on GLP-1 agonist drugs. That’s up from $81 million in ...

Gov. Joe Lombardo’s sweeping health care bill, introduced Thursday, would create a state office of mental health, accelerate the licensing process for health care providers and invest millions with the goal of increasing access into underserved areas. Senate Bill 495, the Nevada Healthcare Access Act — which Lombardo deemed one of his priority bills during ...

Tens of thousands of Nevadans could pay less each month for insulin if lawmakers approve a proposed out-of-pocket cap on commercial insurance plans, according to the state Division of Insurance. Assembly Bill 555, sponsored by Speaker Steve Yeager, would prohibit private insurance companies from charging people more than $35 for a 30-day supply of a ...

The Southern Nevada Health District (SNHD) has released its latest Community Health Assessment Report (CHA). It includes data the district began gathering in 2024. The report, which comes out every three to five years, identified eight areas of public health concern in Southern Nevada: social determinants of health, access to care, mental health, chronic disease, public health ...

The price of weight loss drugs is falling. Wegovy and Zepbound, which both sell for a list price of more than $1,000 a month, have long been out of reach for people without insurance or whose insurance refused to cover them. Among adults who take the medications, about half say it’s difficult to afford the cost, ...

Costs for the average person increased by 6.7% to $7,871 in 2025 led by a 9.7% hike in pharmacy expenses and an 8.5% rise in outpatient facility care costs.